Home›Companies›Biotech & Pharma›Hinge Bio

Hinge Bio, Inc.

Updated Oct 27, 2026·Latest SEC filing Jan 15, 2025·Suggest an edit

About Hinge Bio

Hinge Bio is a private company based in Burlingame, California. It has reported $66,788,127 raised in three offerings on Form D since February 2020. Its chief executive is Harold Selick, PhD.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Dec 31, 2024Jan 15, 2025$30,596,388of $40.8M target82$373KEquityRule 506(b)Form D ↗
Dec 18, 2020Jan 7, 2021amended Feb 1, 2021$18,000,000fully sold77$233KDebt, Convertible Promissory Notes.Rule 506(b)Form D/A ↗2 earlier filings
Feb 11, 2020Feb 27, 2020amended Apr 28, 2020$18,191,739of $19.0M target100$181KEquity, OptionsRule 506(b)Form D/A ↗1 earlier filing
Total, three offerings$66,788,127

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Hinge Bio's Form D filed Jan 15, 2025.

JP
MG
HP
Harold Selick, PhD
Chief Executive Officer and director
MS
Miriam Siekevitz
Executive officer

Earlier filings also listed William Unger (director, last listed Feb 2021), Daniel Capon (executive officer and director, last listed Feb 2021), Carin Rollins (ceo and director, last listed Feb 2021), Samuel Saks (director, last listed Apr 2020) and J. Petkevich (director, last listed Apr 2020).

Sources

  1. SECHinge Bio, Inc. Form D/A, filed Jan 14, 2021
  2. SECHinge Bio, Inc. Form D, filed Jan 7, 2021
  3. SECHinge Bio, Inc. Form D, filed Feb 27, 2020
  4. SECHinge Bio, Inc. filing history